Q2058 Obecbtge autol up to 400 mil
Also known as: Pelsmaplimab, obecabtagene autoleucel, CAR-T
Obecabtagene autoleucel CAR-T cell immunotherapy up to 400 million cells for CD19-positive hematologic malignancies.
In Plain Language
cancer cell fighter; engineered cell therapy
Clinical Context
Next-generation CAR-T therapy for CD19+ hematologic malignancies with up to 400 million cell dose for enhanced efficacy.
RVU Information
CPT Q2058 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2058?
CPT Q2058 (Obecbtge autol up to 400 mil) is a Q Codes code. Obecabtagene autoleucel CAR-T cell immunotherapy up to 400 million cells for CD19-positive hematologic malignancies.
Is Q2058 covered by insurance?
Q2058 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Next-generation CAR-T therapy for CD19+ hematologic malignancies with up to 400 million cell dose for enhanced efficacy.
When is CPT Q2058 used?
Next-generation CAR-T therapy for CD19+ hematologic malignancies with up to 400 million cell dose for enhanced efficacy.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.